• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

AstraZeneca - Articles and news items

anti-infective drug pfizer

Pfizer to acquire AstraZeneca’s anti-infective business

Industry news / 24 August 2016 / Pfizer

The agreement includes the rights to the newly approved EU drug zavicefta (ceftazidime-avibactam), the marketed agents merrem/meronem (meropenem) and zinforo (ceftaroline fosamil), and the clinical development assets aztreonam-avibactam (ATM-AVI) and CXL…

Alzheimer's disease definition

AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease

Industry news / 23 August 2016 / AstraZeneca

AstraZeneca and Eli Lilly and Company have received US FDA Fast Track designation for the development programme in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in Phase III clinical trial.


NICE recommends thousands to receive £2-a-day anti-clotting drug

Industry news / 15 August 2016 / National Institute for Health and Care Excellence (NICE)

A higher dose of ticagrelor is already recommended for 12 months after a heart attack. Now new draft guidance is recommending it is continued in these people at a lower dose for a further three years to reduce their risk of a further heart attack or stroke…

broken pill cancer

Unsuccessful and disappointing clinical trials for AstraZeneca’s lung cancer drug

Industry news / 9 August 2016 / AstraZeneca

The results showed that the trial did not meet its primary endpoint of progression-free survival (PFS), and selumetinib did not have a significant effect on overall survival (OS). The adverse event profiles for selumetinib and docetaxel were consistent with those seen previously…


Initiation of HTL1071 trial triggers $10m payment to Heptares

Industry news / 6 July 2016 / Victoria White, Digital Content Producer

The first subject has been dosed with immuno-oncology candidate HTL1071 in a Phase I clinical study, triggering a US$10 million payment to Heptares…

leo pharma

AstraZeneca licenses skin disease drugs to LEO Pharma

Industry news / 1 July 2016 / Victoria White, Digital Content Producer

AstraZeneca has entered into an agreement with LEO Pharma for the global licence to tralokinumab in skin diseases.


AstraZeneca’s new antibiotic Zavicefta approved in the EU

Industry news / 28 June 2016 / Victoria White, Digital Content Producer

The EC has granted marketing authorisation for Zavicefta for the treatment of patients with serious Gram-negative bacterial infections…


Expanded Phase II trial of savolitinib in NSCLC starts

Industry news / 20 June 2016 / Victoria White, Digital Content Producer

Savolitinib is a potential global first-in-class inhibitor of c-Met, an enzyme which has been shown to function abnormally in many types of solid tumours…


AGI acquires rights to AstraZeneca’s anaesthetics portfolio outside US

Industry news / 9 June 2016 / Victoria White, Digital Content Producer

AGI is to acquire the rights, outside the US, to AstraZeneca’s portfolio of anaesthetics for an upfront consideration of $520 million…


AstraZeneca licenses gout drug Zurampic to Grünenthal

Industry news / 2 June 2016 / Victoria White, Digital Content Producer

Grünenthal has entered into a licensing agreement with AstraZeneca for the exclusive rights to Zurampic (lesinurad) in Europe and Latin America…


Faslodex demonstrates superiority to Arimidex in Phase III study

Industry news / 27 May 2016 / Victoria White, Digital Content Producer

The Phase III FALCON trial compared Faslodex to Arimidex for the treatment of locally-advanced or metastatic breast cancer, in post-menopausal women…


Selumetinib granted Orphan Drug Designation in the US for DTC

Industry news / 12 May 2016 / Victoria White, Digital Content Producer

The FDA has granted Orphan Drug Designation for selumetinib for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer (DTC)…


Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +